Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2019-06-10 Regulatory Filings
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Ascelia Pharma strengthens its Mangoral franchise by filing of a patent application for next generation Mangoral product
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Ascelia Pharma has filed a patent application for a next-generation product ('Mangoral'). This action relates to intellectual property protection and product lifecycle management, which is a strategic corporate activity. It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a standard regulatory filing (RNS) for general news. It is most closely related to corporate strategy and asset protection. Since there is no specific category for 'Patent Filing' or 'Intellectual Property Update', and it is a strategic announcement concerning the company's assets and future value proposition, it fits best under 'Capital/Financing Update' (CAP) if interpreted broadly as corporate value enhancement, or potentially 'Regulatory Filings' (RNS) as a fallback. However, given the focus on extending exclusivity rights and improving a core asset, it is a significant corporate action. Comparing the options, it is not M&A (TAR), not a management change (MANG), and not a general regulatory announcement (RNS). It is a specific update on a key asset's protection. Since it is a specific announcement about an action taken to secure future value (patent filing), and not a general regulatory filing, I will classify it as a Capital/Financing Update (CAP) as it directly impacts the company's long-term capital value proposition, although 'RNS' is a close secondary option if the scope of CAP is too narrow. Given the context of financial reporting databases, updates on core IP protection that extend exclusivity until 2040 are often grouped with major corporate value events. I will select RNS as the most appropriate general category for specific, non-financial, non-management corporate announcements that don't fit elsewhere, as patent filings are often disclosed via regulatory news services.
2019-06-10 English
Ascelia Pharma stärker ställningen för Mangoral med en patentansökan för nästa generations Mangoral-produkt
Investor Presentation Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces that Ascelia Pharma has filed a patent application for a next-generation product (Mangoral). It discusses intellectual property rights extension, product improvement, and upcoming clinical trial phases (Phase III). This type of announcement, detailing specific corporate actions, product development milestones, or legal/IP updates, is generally classified as a general regulatory announcement or a specific update if a category fits. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it specifically concerns intellectual property and product development, it fits best under the general regulatory filing category (RNS) as it is a formal public disclosure of a material event, or potentially a Legal Proceedings Report (LTR) if the focus was purely legal, but here it is a business/IP update. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for a general press release announcing a significant corporate event like a patent filing, especially since it doesn't fit the specific financial or governance categories. The document length (3789 chars) is short, but it is the primary announcement, not just an announcement *of* an attached report, so RPA is less suitable than RNS for this type of substantive news release.
2019-06-10 Swedish
Earnings Release 2019
Earnings Release Classification · 99% confidence The document is titled "DELÅRSRAPPORT Januari – mars 2019" (Interim Report January – March 2019) and contains a "FINANSIELL SAMMANFATTNING KV3 (JAN-MAR 2019)" (Financial Summary Q3 (Jan-Mar 2019)) with key financial figures (Operating result, EPS, Cash flow, Liquid funds) for the period. It also includes a CEO's statement discussing business developments, financing (a successful IPO), and clinical pipeline progress (Mangoral Phase III planning, Oncoral Phase I results). This structure—a comprehensive financial review for a period shorter than a year, including management discussion—is characteristic of an Interim Report. It is not a 10-K (Annual Report) because the period is Q1/Q3, not the full year. It is not a simple Earnings Release (ER) because it is detailed and comprehensive, including strategy and pipeline updates beyond just the headline numbers. It is too detailed to be a Fund Information/Factsheet (FS). Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q1 2019
2019-05-15 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period 'January – March 2019'. It contains substantive financial data, including operating results, earnings per share, cash flow, and cash equivalents for the quarter. It also includes detailed management commentary, business strategy, and clinical trial updates. As it is a comprehensive financial report for a period shorter than a full fiscal year, it fits the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-15 English
Ascelia Pharma håller telekonferens för presentation av kvartalsrapport
Report Publication Announcement Classification · 98% confidence The document is a press release dated May 13, 2019, announcing that Ascelia Pharma's quarterly report (kvartalsrapport) for January – March 2019 (Q3 2018/2019) will be published on May 15, 2019. It explicitly states that a presentation for analysts, media, and investors will follow the report release. Since the document's primary function is to announce the upcoming publication of a financial report and the associated conference call, it fits the definition of a Report Publication Announcement (RPA). The document length (2042 chars) is short, supporting the 'MENU VS MEAL' rule, as it is announcing the report rather than being the comprehensive report itself (which would likely be an IR or ER).
2019-05-13 Swedish
Ascelia Pharma to host teleconference for presentation of interim financial report
Report Publication Announcement Classification · 98% confidence The document is a press release dated May 13, 2019, announcing that Ascelia Pharma's 'interim financial report for the period January – March 2019 (Q3 2018/2019)' will be published on May 15, 2019. The primary purpose of this text is to schedule and invite participants to a teleconference/presentation following the release of the interim report. Since the document itself is not the comprehensive interim report (IR) but rather an announcement about its upcoming publication and associated call, it fits the definition of a Report Publication Announcement (RPA). The document length (2123 chars) is short, supporting the 'MENU VS MEAL' rule.
2019-05-13 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.